COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Processing of Music in Alzheimer Patients (MUKU-DEM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04132193
Recruitment Status : Not yet recruiting
First Posted : October 18, 2019
Last Update Posted : October 25, 2019
University of Turku
Information provided by (Responsible Party):
Seppo Soinila, Turku University Hospital

Brief Summary:
Correlation of musicality, brain atrophy in brain areas relevant for music processing and the stage of Alzheimer´s disease.

Condition or disease
Alzheimer Disease Dementia Amusia

Detailed Description:

Alzheimer's disease (AD) is the most common cause of dementia accounting for 60-70% of all dementias. In most cases the cause for AD is unknown. The progression of AD is characterized by an advancing decline in cognitive skills and symptoms like impaired learning, memory deficits, language impairment and behavioral disturbances in later stages. The symptoms of AD are caused by cerebral atrophy which is the consequence of multiple pathological processes, including the formation of neurofibrillary tangles at neurites and amyloid plaques in the walls of cerebral blood vessels. AD is a major public health issue and its significance increases as the population grows older.

Music is thought to have preceded the development of spoken language as a form of communication and it has been used for therapeutic purposes in many ways throughout history. In patients with AD, musical memory has been noticed to be well-preserved and constituting a relatively independent part of memory. Music-based neurological rehabilitation provides a mode of treatment, which is free of side effects and can be personalized for patients with dementia.

Aims of this study are to examine how AD affects the structure of various brain areas associated with music processing and to statistically correlate musical cognition with memory performance in patients with AD. Focus is on brain areas associated with musical pleasure like the striatum, superior temporal gyrus, inferior frontal gyrus and areas associated with long-term musical memory like the anterior cingulate gyrus and presupplementary motor area. Hippocampal atrophy serves as a reference of the stage of AD. Our working hypothesis is that musicality correlates with preserved cognitive skills and memory.

Voluntary participants who have been diagnosed with AD are recruited from Turku University Central Hospital. Their musicality is assessed with a short version of Montreal Battery of Evaluation of Amusia which contains listening tasks that test the patients' memory, rhythm recognition and pitch discrimination. In addition, patients are asked to fill an inquiry that maps their use of music and its significance in their daily lives. Voxel-Based Morphometry is applied on MRI images to evaluate atrophy in the hippocampus and entorhinal cortex, which correlate with clinical stages of AD, as well as on the brain areas relevant for processing of music.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Correlation of Musicality and Cognitive Skills in Persons With Alzheimer´s Disease
Estimated Study Start Date : October 2019
Estimated Primary Completion Date : May 2020
Estimated Study Completion Date : May 2021

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Montreal Battery of Evaluation of Amusia [ Time Frame: 60 minutes ]
    Number of correct answers in three task collections (total 79 tasks)

  2. Brain atrophy in MRI scans [ Time Frame: 120 minutes ]
    Loss of volume in brain regions relevant for music processing and in the hippocampi estimated by voxel-based morphometry

  3. CERAD (Consortium for Establishing Registry of Alzheimer´s Disease) [ Time Frame: 30 minutes ]
    Level of cognitive impairment

Secondary Outcome Measures :
  1. Use of music in patient´s daily life [ Time Frame: 30 minutes ]
    Validated self-report questionnaire MusEQ in Finnish, Likert scale 1-5 (Vanstone AD et al, Aging Ment Health 2016)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
Patients of Southwest Finland Hospital District

Inclusion Criteria:

Diagnosed Alzheimer´s disease

Exclusion Criteria:

Other neurological comorbidity, substance abuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04132193

Layout table for location contacts
Contact: Seppo Soinila, MD PhD +358503463396
Contact: Pavel Zaitsev, B.Sc.

Sponsors and Collaborators
Turku University Hospital
University of Turku
Layout table for investigator information
Principal Investigator: Seppo Soinila, MD PhD Turku University Hospital
Layout table for additonal information
Responsible Party: Seppo Soinila, professor, chief physician, Turku University Hospital Identifier: NCT04132193    
Other Study ID Numbers: T112/2019
First Posted: October 18, 2019    Key Record Dates
Last Update Posted: October 25, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders